iPSC-derived RPE/PLGA transplantation
Asset
Replaces damaged retinal pigment epithelium with autologous induced pluripotent stem cell-derived cells on a biodegradable scaffold.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Trial NCT04339764 is still running. Trial NCT04339764 updated in its registry on Nov 12, 2026. clinicaltrials.gov
Indications
2Dry age-related macular degeneration
Phase 1, Recruiting, NCT04339764, clinicaltrials.gov, Oct 17, 2026
Geographic atrophy
Phase 1, Recruiting, NCT04339764, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors5
Every asset’s record: target, stage, trials and the evidence behind it.